Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in <i>BRAF<sup>V600E</sup></i>-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study

Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in <i>BRAF<sup>V600E</sup></i>-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study

<i>Background and Objectives</i>: Approximately 5–10% of all patients with metastatic colorectal cancer (mCRC) harbor a <i>BRAF<sup>V600E</sup></i> mutation. These patients exhibit distinct metastatic patterns, poor prognosis, and heterogenous survival outcomes. T...

Full description

Bibliographic Details
Main Authors: Hsiang-Lin Tsai, Ching-Wen Huang, Yen-Cheng Chen, Wei-Chih Su, Tsung-Kun Chang, Po-Jung Chen, Ching-Chun Li, Yu-Tang Chang, Jaw-Yuan Wang
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Medicina
Subjects:
<i>BRAF<sup>V600E</sup></i> mutation
metastatic colorectal cancer
<i>UGT1A1</i> polymorphism
irinotecan dose escalation
progression-free survival
overall survival
Online Access:https://www.mdpi.com/1648-9144/59/12/2108

Internet

https://www.mdpi.com/1648-9144/59/12/2108

Similar Items